Th17-cells in depression: Implication in multiple sclerosis

Mikhail Melnikov; Anna Lopatina

doi:10.3389/fimmu.2022.1010304

Th17-cells in depression: Implication in multiple sclerosis

Front Immunol. 2022 Sep 14:13:1010304. doi: 10.3389/fimmu.2022.1010304. eCollection 2022.

Authors

Mikhail Melnikov^{1

2

3}, Anna Lopatina¹

Affiliations

¹ Department of Neuroimmunology, Federal Center of Brain Research and Neurotechnology of the Federal Medical-Biological Agency of Russia, Moscow, Russia.
² Department of Neurology, Neurosurgery and Medical Genetics, Pirogov Russian National Research Medical University, Moscow, Russia.
³ Laboratory of Clinical Immunology, National Research Center Institute of Immunology of the Federal Medical-Biological Agency of Russia, Moscow, Russia.

Abstract

Depression is one of the most common neuropsychological symptoms of multiple sclerosis. However, in addition to mood disorder, depression can also influence on multiple sclerosis course. The mechanism of this dependence is not fully understood. The recent studies suggest the possible common immune mechanisms in the pathogenesis of depression and multiple sclerosis. In particular, it was shown that along with biogenic amines disturbance, neuroinflammation also play an important role in the pathogenesis of depression. Significant attention is drawn to Th17-cells subsets, which are considered as critical players in the pathogenesis of inflammatory diseases of the central nervous system, including multiple sclerosis. This brief report reviews the literature data on the role of neuroinflammation in the reciprocal influence of multiple sclerosis and depression with focus on Th17-cells, which may underlie pathogenetic mechanisms of both this diseases.

Keywords: Th17-cells; antidepressants; depression; multiple sclerosis; neuroinflammation.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Biogenic Amines
Central Nervous System
Depression
Humans
Multiple Sclerosis*
Th17 Cells

Substances

Biogenic Amines